

Docket No.: 61386(72021)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Rajagopal Bakthavatchalam et al.

Application No.: 10/591,568

Confirmation No.: 6247

Filed: September 1, 2006

Art Unit: 1614

For: ARALKYLAMINO-SUBSTITUTED
QUINAZOLINE ANALOGUES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61386(72021).

Dated: July 9, 2007

Respectfully submitted,

By 
Mark D. Russett

Registration No.: 41,281
EDWARDS ANGELL PALMER & DODGE
LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 239-0100
Attorneys/Agents For Applicant

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 61386(72021)

Complete If Known

Application Number	10/591,568
Filing Date	September 1, 2006
First Named Inventor	Rajagopal Bakthavatchalam
Art Unit	1614
Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS
Examiner Initials* Cite No. ¹ Document Number Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

AA	US 2004/0106616	06/03/2004	Bakthavatchalam et al.	
AB	US 2004/0156869	08/12/2004	Bakthavatchalam et al.	
AC	US 2005/0215575	09/29/2005	Bakthavatchalam et al.	
AD	US 2005/0070547	03/31/2005	Bakthavatchalam et al.	
AE	US 2007/0105865	05/10/2007	Bakthavatchalam et al.	
AF	5,034,393	07/23/1991	Hackler et al.	
AG	5,436,233	07/25/1995	Lee et al.	
AH	5,326,766	07/05/1994	Dreikorn et al.	
AI	5,112,817	05/12/1992	Fukazawa et al.	
AJ	4,694,000	09/15/1987	Timmerman et al.	
AK	4,352,928	10/05/1982	Hiranuma et al.	
AL	3,971,783	07/27/1976	Barnish et al.	
AM	US-2006-0089354-A1	04/27/2006	Bakthavatchalam et al.	
AN	US-2003/0191312	10/09/2003	Sheng Ding	

FOREIGN PATENT DOCUMENTS					T ⁶			
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document				
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)						

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
CA	JOHANSEN, M.E. et al., "TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV1-Mediated Toxicities in Human Lung Epithelial Cells", <i>Toxicological Sciences</i> 89(1), 278-286 (2006) (Advance Access publication August 24, 2005)						
CB	THOMAS, Karen C. et al., "Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 321(3), 830-838 (2007).						
CC	BOLCSKEI, Kata et al., "Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice," <i>Pain</i> 117, 368-376 (2005).						
CD	HELYES, Zsuzsanna et al., "Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse," <i>Am J Physiol Lung Cell Mol Physiol</i> , 292(5):L1173-81 (2007).						
CE	BANVOLGYI, Agnes et al., "Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model," <i>J Neuroimmunol</i> . 169, 86-96 (2005).						
CF	International Search Report for PCT/US2005/06697 (4 pages)						
CG	International Preliminary Report on Patentability for PCT/US2005/06697 (6 pages)						
CH	MAKI, Yoshifumi et al., "N ⁷ - Alkylation and Ring-Transformation of N ⁶ - Acyl-9-Substituted Adenines," <i>Heterocycles</i> (p.895-898). (1981)						
CI	Temple, Carroll Jr. et al., "Synthesis of Potential Antimalarial Agents. II. 6,8-Disubstituted Pyrido[2,3-b]pyrazines," (p.1216-1218). (1968)						
CJ	Nishikawa, Kohei et al., "Structure-Activity Relationships of the Diuretic Activity of Triaza- and Tetraaza-Naphthalene Compounds," <i>Chemical & Pharmaceutical Bulletin</i> p. 2057-2077. (1976)						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------